zynex.com - יחס שווי חברה להכנסות ZYXI

Zynex, Inc. (ZYXI) ensures stable income due to the defensive nature of pain therapy, which makes the business crisis-resistant. The GURU.Markets system displays this price-to-sales ratio, where 0.00 is the current level of the metric. Growth is based on expanding the sales force without mergers, while high protection is guaranteed by strict FDA control and patents.
ZYXI (Zynex Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The specific nature of Zynex, Inc. (ZYXI) within the medtech sector makes the enterprise value-to-revenue ratio sensitive to regulatory approvals and component supply chain stability. This indicator compares the total enterprise value (EV) with annual turnover, excluding the impact of leverage, which allows investors to assess the actual market premium paid per unit of sales regardless of the company's debt load.